Recent news on Capromab

Outcomes Data Continue to Demonstrate Value of Cytogen’s ...  -  May 22, 2007
Business Wire (press release),PROSTASCINT ® (capromab pendetide) is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer and SOLTAMOX

Cytogen Reports First Quarter 2007 Financial Results  -  May 10, 2007
PharmaLive.com (press release),Cytogen's product revenues were comprised of sales of QUADRAMET(R) (samarium Sm-153 lexidronam injection) and PROSTASCINT(R) (capromab pendetide).

New Clinical Data for PROSTASCINT® and QUADRAMET® in Prostate ...  -  Feb 24, 2007
Business Wire (press release),...“Impact of capromab pendetide scanning in a selection of prostate cancer treatments compared to clinical risk factors alone� (Abstract No. 189)

Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN ...  -  Jan 4, 2007
American Digital Networks (press release),Cancer Network (NCCN) has included PROSTASCINT(R) (capromab pendetide) in its updated clinical practice guidelines for recurrent prostate cancer.

Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN ...  -  Jan 4, 2007
Genetic Engineering News (press release),Cytogen Corporation (NASDAQ: CYTO) today reported that the National Comprehensive Cancer Network (NCCN) has included PROSTASCINT(R) (capromab pendetide) in

Combination of High Dose QUADRAMET(R) and Chemotherapy Shows ...  Sep 18, 2006
Cytogen's marketed products include QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide) kit for the preparation of Indium In ... -Yahoo! News

Cancer Patients Show Reduced Pain And Lower Analgesic Consumption ...  Sep 20, 2006
Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection), PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium ... -Medical News Today

Cytogen Corporation and Mayor Rudy Giuliani to Ring in Prostate ...  29 Aug 2006
Cytogen's marketed products include QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide) kit for the preparation of Indium In ... -Yahoo! News



Cytogen Announces FDA Clears IND For CYT-500, A Monoclonal ...  May 9, 2006
CYT-500 uses the same monoclonal antibody from Cytogen's PROSTASCINT(R) (capromab pendetide) molecular imaging agent, but is linked through a higher affinity ... - Medical News Today

Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ...  May 11, 2006
Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection), PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium ... - Genetic Engineering News

Cytogen Corporation to Present at the Rodman & Renshaw 3rd Annual ...  May 9, 2006
Cytogen's marketed products include QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide) kit for the preparation of Indium In ... - Yahoo! News

Cytogen Reports First Quarter 2006 Financial Results  May 8, 2006
...and is currently available on the AUA website at http://www.auanet.org, which is not part of this press release: -- "SPECT/CT Capromab Pendetide Independently ... - Yahoo! News

Cytogen antibody gets FDA trial OK  May 9, 2006
CYT-500 uses the same monoclonal antibody from Cytogen's Prostascint (capromab pendetide) molecular imaging agent, but is linked through a higher affinity ... - Pharmaceutical Business Review

Cytogen Sells Ownership in PSMA Development Joint Venture to ...  Apr 24, 2006
CYT-500 incorporates the same monoclonal antibody utilized in Cytogen's PROSTASCINT® (capromab pendetide) molecular imaging agent, but is linked to a ... - Yahoo! News

Cytogen tests antibody for prostate cancer  May 8, 2006
The company said the treatment incorporates the same monoclonal antibody as that used in Cytogen's Prostascint (capromab pendetide) molecular imaging agent and ... - United Press International

Cytogen Selling PSMA Joint Venture Share To Progenics  Apr 24, 2006
It incorporates the same monoclonal antibody used in Cytogen's Prostascint (capromab pendetide) molecular imaging agent, but is linked to a therapeutic as ... - BioWorld Online (subscription)





Cytogen Announces Submission of IND for CYT-500 for the Treatment ...  Apr 6, 2006
CYT-500 incorporates the same monoclonal antibody utilized in Cytogen's PROSTASCINT® (capromab pendetide) molecular imaging agent, but is linked to a ... - Yahoo! News

New Study Shows QUADRAMET(R) May Enhance Immune System Recognition ...  Apr 4, 2006
Cytogen's marketed products include QUADRAMET® (samarium Sm-153 lexidronam injection) and PROSTASCINT® (capromab pendetide) kit for the preparation of Indium ... - Yahoo! News

Cytogen Announces Schedule for Clinical Data Presentations at ...  Mar 23, 2006
The company also announced that clinical data from a recent study involving its second marketed product, PROSTASCINT(R) (capromab pendetide), will be presented ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional